Germany first in EU to get Novartis' SMA gene therapy, costi...

Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced at 1,945,000 euro

Novartis offers reimbursement options as EU backs costly SMA...

Novartis’ AveXis unit has said European regulators have approved its Zolgensma (onasemnogene abeparvovec) gene therapy for the rare childhood wasting disease spinal muscular atrophy (SMA),

Novartis closes on EU approval for SMA gene therapy Zolgensm...

AveXis rules out EU compassionate use of SMA gene therapy, s...

Novartis’ AveXis unit has given its reasons for refusing to supply its spinal muscular atrophy gene therapy Zolgensma to a seriously ill child in Belgium, saying compassionate use rules do

Gene Therapy Analytical Development

In the context of unprecedented gene therapy clinical progress and mounting regulatory scrutiny, the inaugural Gene Therapy Analytical Development Summit will unite large pharma an

Weekly roundup: More questions for Novartis in Zolgensma sca...

It’s been a tough month for Novartis, with the company facing a deepening scandal over data manipulation for its spinal muscular atrophy (SMA) gene therapy Zolgensma.